TY - JOUR
T1 - Haemochromatosis in children
T2 - A national retrospective cohort promoted by the A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica) study group
AU - Corti, Paola
AU - Ferrari, Giulia Maria
AU - Faraguna, Martha Caterina
AU - Capitoli, Giulia
AU - Longo, Filomena
AU - Corradini, Elena
AU - Casini, Tommaso
AU - Boscarol, Gianluca
AU - Pinto, Valeria Maria
AU - Ghilardi, Roberta
AU - Russo, Giovanna
AU - Colombatti, Raffaella
AU - Mariani, Raffaella
AU - Piperno, Alberto
N1 - Publisher Copyright:
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - Haemochromatosis (HC) encompasses a range of genetic disorders. HFE-HC is by far the most common in adults, while non-HFE types are rare due to mutations of HJV, HAMP, TFR2 and gain-of-function mutations of SLC40A1. HC is often unknown to paediatricians as it is usually asymptomatic in childhood. We report clinical and biochemical data from 24 paediatric cases of HC (10 cases of HFE-, 5 TFR2-, 9 HJV-HC), with a median follow-up of 9.6 years. Unlike in the adult population, non-HFE-HC constitutes 58% (14/24) of the population in our series. Transferrin saturation was significantly higher in TFR2- and HJV-HC compared to HFE-HC, and serum ferritin and LIC were higher in HJV-HC compared to TFR2- and HFE-HC. Most HFE-HC subjects had relatively low ferritin and LIC at the time of diagnosis, so therapy could be postponed for most of them after the age of 18. Our results confirm that HJV-HC is a severe form already in childhood, emphasizing the importance of early diagnosis and treatment to avoid the development of organ damage and reduce morbidity and mortality. Although phlebotomies were tolerated by most patients, oral iron chelators could be a valid option in early-onset HC.
AB - Haemochromatosis (HC) encompasses a range of genetic disorders. HFE-HC is by far the most common in adults, while non-HFE types are rare due to mutations of HJV, HAMP, TFR2 and gain-of-function mutations of SLC40A1. HC is often unknown to paediatricians as it is usually asymptomatic in childhood. We report clinical and biochemical data from 24 paediatric cases of HC (10 cases of HFE-, 5 TFR2-, 9 HJV-HC), with a median follow-up of 9.6 years. Unlike in the adult population, non-HFE-HC constitutes 58% (14/24) of the population in our series. Transferrin saturation was significantly higher in TFR2- and HJV-HC compared to HFE-HC, and serum ferritin and LIC were higher in HJV-HC compared to TFR2- and HFE-HC. Most HFE-HC subjects had relatively low ferritin and LIC at the time of diagnosis, so therapy could be postponed for most of them after the age of 18. Our results confirm that HJV-HC is a severe form already in childhood, emphasizing the importance of early diagnosis and treatment to avoid the development of organ damage and reduce morbidity and mortality. Although phlebotomies were tolerated by most patients, oral iron chelators could be a valid option in early-onset HC.
KW - haemochromatosis
KW - hyperferritinaemia
KW - iron chelation
KW - juvenile haemochromatosis
KW - phlebotomy
UR - http://www.scopus.com/inward/record.url?scp=85177645765&partnerID=8YFLogxK
U2 - 10.1111/bjh.19208
DO - 10.1111/bjh.19208
M3 - Article
C2 - 37990447
AN - SCOPUS:85177645765
SN - 0007-1048
VL - 204
SP - 306
EP - 314
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -